<DOC>
	<DOCNO>NCT02967380</DOCNO>
	<brief_summary>This pilot clinical trial compare gadobutrol standard care contrast agent , gadopentetate dimeglumine gadobenate dimeglumine , dynamic contrast-enhanced ( DCE ) -magnetic resonance imaging ( MRI ) diagnose patient multiple sclerosis , grade II-IV glioma , tumor spread brain . Gadobutrol type contrast agent may increase DCE-MRI sensitivity detection tumor diseases central nervous system . It yet know whether gadobutrol effective standard care contrast agent DCE-MRI diagnose patient multiple sclerosis , grade II-IV glioma , tumor spread brain .</brief_summary>
	<brief_title>Gadobutrol Versus Gadopentetate Dimeglumine Gadobenate Dimeglumine Before DCE-MRI Diagnosing Patients With Multiple Sclerosis , Grade II-IV Glioma , Brain Metastases</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether Gadavist® ( gadobutrol ) consistent Magnevist® ( gadopentetate dimeglumine ) Multihance ( gadobenate dimeglumine ) preoperative grade glioma utilize DCE MRI . II . To determine whether Gadavist® consistent Magnevist® Multihance identify number cerebral metastasis primary cancer elsewhere body use T1-weighted post contrast MRI . III . To determine Gadavist® consistent Magnevist® Multihance identify multiple sclerosis ( MS ) plaques use T1-weighted post contrast MRI . IV . To determine Gadavist® produce similar MR perfusion/permeability value MS lesion Magnevist® Multihance . V. Descriptive analysis present different rating pattern Gadavist® versus Magnevist® Multihance differentiate therapeutic necrosis recurrent tumor glioma utilize DCE MRI . OUTLINE : Patients receive standard care gadopentetate dimeglumine intravenously ( IV ) twice within 5 minute gadobenate dimeglumine IV twice within 5 minute undergo DCE-MRI day 1 . Patients also receive gadobutrol IV twice within 5 minute undergo DCE-MRI approximately 30 minute day 3 , 4 , 5 , 6 , 7 . After completion study , patient follow 7 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<criteria>Confirmed diagnosis multiple sclerosis , know suspected diagnosis glioma , know suspected diagnosis cerebral metastasis Scheduled schedule followup MRI per standard care disease Minimum permit time interval prior treatment 6 week intracranial surgery Adequate renal function ( serum creatinine = &lt; 1.5 mg/dL ) Subject must sign studyspecific inform consent Medically unstable Renal impairment ( glomerular filtration rate [ GFR ] &lt; 60 mL/min/1.73m^2 ) history exist nephrogenic systemic fibrosis ( NSF ) Cardiac pacemaker A serious concurrent infection , illness , medical condition Subjects surgical clip , external clip , ferromagnetic device , contraindicate use MRI Subject claustrophobic cooperate MRI Females pregnant nursing Any condition would compromise scan reasonable safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>